Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.
-
Upload
logan-davidson -
Category
Documents
-
view
212 -
download
0
Transcript of Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.
![Page 1: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/1.jpg)
Diabetes Type 2: Tight Diabetes Type 2: Tight ControlControl
Sufyan Said, M.D.Staff Physician, CAVHS
Assistant Professor, UAMS
![Page 2: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/2.jpg)
Definition of Diabetes Definition of Diabetes MellitusMellitus
Diabetes Mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both
The chronic hyperglycemia of diabetes is associated long-term damage, dysfunction, and failure of various organs, especially in the eyes, kidneys, nerves, heart and blood vessels.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care. 1998;21(suppl 1):S5-S19
![Page 3: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/3.jpg)
1998 Criteria for the Diagnosis of Diabetes 1998 Criteria for the Diagnosis of Diabetes MellitusMellitus
(Each must be confirmed on a subsequent day.) Symptoms of Diabetes* plus casual† plasma
glucose concentration 200mg/dlOr
Fasting plasma glucose‡ 126 mg/dlOr
2-h plasma glucose 200 mg/dl during an OGTT§
* Classic Symptoms = polyuria, polydipsia, and unexplained weight loss.† Casual = any time of the day without regard to time since last meal.‡ Fasting = no calori intake for at least 8 h.§ Requires use of a glucose (75 gm) load.OGTT = oral glucose tolerance test.The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care. 1998;21(suppl 1):S5-S19
![Page 4: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/4.jpg)
Estimated Prevalence (20- 79 age Estimated Prevalence (20- 79 age group)group)
Country Prevalence
(%)
Country Prevalence
(%)
Papua New Guinea
15.5 Aruba, Bermuda, British Virgin
Islands, Cayman Islands, Grenada,
Hong Kong, St Kitts, Nevis
12.1Mauritius 15.0
Bahrain 14.8
Mexico 14.2
Trinidad
Tobago
14.1 Pakistan 11.8
Czech Republic 11.7
Barbados 13.2 Tonga 11.5
IDF D I A B E T E S 2000 executive summary page 10
![Page 5: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/5.jpg)
Estimated number in millions of people Estimated number in millions of people with diabetes (20- 79 age group)with diabetes (20- 79 age group)
IDF D I A B E T E S 2000 executive summary page 10
country millionsIndia 32.7
China 22.6
USA 15.3
Pakistan 8.8
Japan 7.1
Indonesia 5.7
Mexico 4.4
Egypt 3.4
Brazil 3.3
Italy 3.1
![Page 6: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/6.jpg)
Harris MI et al. Diabetes Care. 1998;21:518-524.
Incidence and Prevalence of Incidence and Prevalence of Diabetes (US)Diabetes (US)
15.7 million Americans have diabetes
Nearly 6% of the population 5.4 million of these people are unaware
they have diabetes Each year, >798,000 Americans
develop diabetes
>2,200 each day
![Page 7: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/7.jpg)
History of DiabetesHistory of Diabetes
1500 BCEarly healers notice that ants are attracted to the urine of people with a mysterious emaciating disease.
150 Aretaeus of Cappodocia writes about diabetes, which he says "melts the flesh."
1000 Greek physicians prescribe exercise, preferably on horseback, to relieve excess urination.
![Page 8: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/8.jpg)
Diabetes is a wonderful affection, not Diabetes is a wonderful affection, not very frequent among men, being a very frequent among men, being a
melting down of the flesh and limbs melting down of the flesh and limbs into urineinto urine
Areteus the Cappadocian, sometime in the second to third century AD
![Page 9: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/9.jpg)
History of DiabetesHistory of Diabetes
1869Paul Langerhans discovers islet cells in the pancreas.
1889 Mehring and Minkowski produce DM in dogs by removing the pancreas.
1921Banting and Best find a pancreatic extract that lowers blood glucose in pancreatectomized dogs.
VOL 101 / NO 4 / APRIL 1997 / POSTGRADUATE MEDICINE
![Page 10: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/10.jpg)
Dr. F.G. Banting, Mr. C.H. Best, Mr. J.B. Collip and Prof. J.J.R. MacLeod discovered insulin in 1921 at the University of Toronto.
![Page 11: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/11.jpg)
History of DiabetesHistory of Diabetes
1923The Nobel Prize for medicine goes to Banting and Macleod for the discovery of insulin.
1950-1980DNA technology allows development of genetically engineered "human" insulin.
1980-1989Blood glucose self- management gives patients greater control and flexibility in managing diabetes.
![Page 12: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/12.jpg)
History of DiabetesHistory of Diabetes
1990-1997More sophisticated insulin analogues are introduced, and multiple injections and insulin pumps offer promise of closer control.
2000 and beyondResearch continues for ways to cure both type I and type II diabetes.
![Page 13: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/13.jpg)
![Page 14: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/14.jpg)
![Page 15: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/15.jpg)
Comparison of clinical, genetic and immunologic Comparison of clinical, genetic and immunologic features of type 1 and type 2 diabetesfeatures of type 1 and type 2 diabetes
Characteristic Type 1 Type 2
Onset Abrupt Progressive
Endogenous insulin Low to absent Normal, elevated or depressed
Ketosis Common Rare
Age at onset Any age Vast majority Adults
Body mass Usually non-obese Obese or nonobese
Family history 10-15% 30%
Twin concordance 30-50% 70-90%
HLA HLA-DR, HLA-DQ Unrelated
Autoantibodies >85% Rare
![Page 16: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/16.jpg)
![Page 17: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/17.jpg)
Visceral Fat Distribution:Visceral Fat Distribution:Normal vs Type 2 DiabetesNormal vs Type 2 Diabetes
Normal Type 2 Diabetes
![Page 18: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/18.jpg)
050
100150200250
Natural History of Type 2 Natural History of Type 2 DiabetesDiabetes
50100150200250300350
Obesity IFG* Diabetes Uncontrolled hyperglycemia
Postmeal glucose
Fasting glucose
Insulin resistance
Insulin level-cell failure
Glucose(mg/dL)
Relative function
(%)
Years of diabetes*IFG=impaired fasting glucose.
-10 -5 0 5 10 15 20 25 30
Adapted from International Diabetes Center (Minneapolis, Minn).
![Page 19: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/19.jpg)
![Page 20: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/20.jpg)
![Page 21: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/21.jpg)
![Page 22: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/22.jpg)
![Page 23: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/23.jpg)
Approach to Treatment of Type 2 Approach to Treatment of Type 2 DiabetesDiabetes
Diet Exercise Weight reduction Oral agents Insulin Careful attention to cardiovascular risk
factors; hypertension, smoking, dyslipidemia and family history
Diabetes Care. 1998;21(suppl 1):S23-S31
![Page 24: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/24.jpg)
Goals of Diet Therapy: Metabolic Control Goals of Diet Therapy: Metabolic Control and Balanceand Balance
Maintenance of as near-normal blood glucose levels as possible
Prevention of acute and long term complications of diabetes
Improvement of overall health through optimal nutrition Adequate calories for maintaining/attaining reasonable
weights for adults, normal growth and development in children and adolescents, increased metabolic needs during pregnancy and lactation, or recovery from catabolic illnesses
Diabetes Care. 1998;21(suppl 1):S32-S35
![Page 25: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/25.jpg)
Treatment to Goal:Treatment to Goal:The Levels of Glycemic ControlThe Levels of Glycemic Control
Biochemical Index Non-diabetic Goal
Additional action
suggested
Fasting glucose*
(mg/dl)
<110 80-120 <80
>140
Bedtime glucose
(mg/dl)
<120 100-140 <100
>160
Hemoglobin A1C
(%)
<6 <7 >8
*Capillary blood valuesHbA1C is referenced to non-diabetic range of 4% to 6%Diabetes Care. 1998;21(suppl 1):S23-S31
![Page 26: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/26.jpg)
Antihyperglycemic Agents:Antihyperglycemic Agents:Major Sites of ActionMajor Sites of Action
Liver
Plasma glucose
GI tract
+
Pancreas
Muscle/Fat
–
Injected Insulin
(–)
(+)
-GlucosidaseInhibitors
(–)Carbohydrat
eAbsorption
Metformin (–)
GlucoseProduction
Glitazones
(+)Glucos
eUptake
InsulinSecretion
SulfonylureasMeglitinides
(+)Insulin
Secretion
![Page 27: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/27.jpg)
Pharmacological approaches to Pharmacological approaches to Treatment of Type 2 DiabetesTreatment of Type 2 Diabetes
Sulfonylureas Glyburide Diabeta,
Micronase, Glynase Glipizide Glucotrol Glimepiride Amaryl
Meglitinides Neteglinide Starlix Rapeglinide Prandin
Biguanides Metformin Glucophage
Thiazolidinediones Pioglitazone Actos Rosiglitazone Avandia
α-Glucosidase Inhibitors
Acarbose Precose Miglitol Glycet
Insulin Several
![Page 28: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/28.jpg)
The The -Glucosidase Inhibitors:-Glucosidase Inhibitors:Basic Characteristics of Acarbose and MiglitolBasic Characteristics of Acarbose and Miglitol
Mechanism of action Delays carbohydrate absorptionDepends upon Postprandial hyperglycemia
Power Decreases HbA1c 0.5% to 1%Dosing Three times dailySide effects FlatulenceMain risk Liver enzyme elevation (rare)
Medical Management of Type 2 Diabetes. 4th ed. Alexandria, Va: American Diabetes Association; 1998:1-139.
![Page 29: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/29.jpg)
The Thiazolidinediones The Thiazolidinediones (Glitazones):(Glitazones):
Basic Characteristics of GlitazonesBasic Characteristics of Glitazones
Mechanism of action Enhance muscle and adiposetissue response to insulin
Depends upon Presence of insulin and resistance to its action
Power Decreases HbA1c 0.5% to 1.5%Dosing Once or twice dailySide effects Edema, weight gain, anemia Main risk Liver failure (? troglitazone only)
![Page 30: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/30.jpg)
The Biguanides:The Biguanides:Basic Characteristics of MetforminBasic Characteristics of Metformin
Data from Bell & Hadden. Endocrinol Metab Clin. 1997;26:523-537; De Fronzo, et al. N Engl J Med. 1995;333:541-549; Bailey & Turner. N Engl J Med. 1996;334:574-579; Medical Management of Type 2 Diabetes. 4th ed. Alexandria, Va: American Diabetes Association; 1998:1-139.
Mechanism of action Decreases hepatic glucoseproduction
Depends upon Presence of insulin
Power Decreases HbA1c 1% to 2%Dosing One to three times dailySide effects Diarrhea, nausea Main risk Lactic acidosis
![Page 31: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/31.jpg)
The Insulin Secretagogues:The Insulin Secretagogues:Basic Characteristics of the Sulfonylureas and Basic Characteristics of the Sulfonylureas and
the Meglitinidesthe Meglitinides
Mechanism of action Increase basal and postprandialinsulin secretion
Depends upon Functioning -cells
Power Decreases HbA1c 1% to 2%
Dosing Once or twice daily (sulfonylureas);three times daily (meglitinides)
Side effects Weight gain
Main risk Hypoglycemia
![Page 32: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/32.jpg)
Practical Management of Type 2 Diabetes Practical Management of Type 2 Diabetes MellitusMellitusFBG >126 mg/dL
Diet and Exercise
126-140 mg/dL 140-200 mg/dL 200-240 mg/dL 240-300 mg/dL >300 mg/dL
GlitazonesMetforminAcarbose
Sx
Insulin
No Sx
Sulfonylurea
No Sx/Sx
Sulfonylurea
Evolving criteria If FBG >140 mg/dL (126 mg/dL?) HbA1c >8% (7%?)
Add second oral agent and titrate to maximum dose
If no improvement: Try triple therapy? Or continue oral agent(s)
+ insulin Rx at PM or HS
Sx
Sulfonylurea
No Sx
SulfonylureaMetformin
Acarbose
Glitazones
Sulfonylurea
Repaglinide
Metformin
Oral Combination Triple Therapy
Monotherapy
![Page 33: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/33.jpg)
Insulin StructureInsulin Structure
![Page 34: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/34.jpg)
![Page 35: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/35.jpg)
Comparison of Human Insulins and Comparison of Human Insulins and AnaloguesAnalogues
Lispro/Aspart 5-15 minutes 1-2 hours 4-6 hours
Human Regular 30-60 minutes 2-4 hours 6-10 hours
Human NPH/Lente 1-2 hours 4-8 hours 10-20 hours
HumanUltralente 2-4 hours Unpredictable 16-20 hours
Glargine 1-2 hours Flat ~24 hours
The time course of action of any insulin may vary in different individuals, or at different times in the same individual. Because of this variation, time periods indicated here should be considered general guidelines only.
Insulin Preparations
Onset of Action Peak
Duration of Action
![Page 36: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/36.jpg)
![Page 37: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/37.jpg)
Moderate intensive therapyModerate intensive therapy
![Page 38: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/38.jpg)
Intensive TherapyIntensive Therapy
![Page 39: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/39.jpg)
Insulin PenInsulin Pen
5-21
![Page 40: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/40.jpg)
![Page 41: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/41.jpg)
1 Pump moves insulin...
2 ...into the Subcutaneous tissue
where it eventually diffuses...
3 ...to the Bloodstream, which slowly
carries the insulin...
4 ...to the Cells where it combines
with the insulin receptors, which
use it to allow glucose to enter
the cell and be metabolized.
![Page 42: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/42.jpg)
![Page 43: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/43.jpg)
![Page 44: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/44.jpg)
GluControl® GC300 by Arthomed Last updated 8-2000 not FDA approved Uses Near-Infrared Quantitative Chemical Analysis.
SugarTrac® NONINVASIVE GLUCOSE MONITOR LifeTrac Systems, Inc. Uses Near-Infrared Quantitative Chemical Analysis. Clinical Trials being conducted in conjunction with Harvard University http://www.sugartrac.com
The Diasensor 2000 available in Europe Biocontrol Technology, Inc FDA is reviewing at this time Uses Near-Infrared Quantitative Chemical Analysis.
![Page 45: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/45.jpg)
![Page 46: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/46.jpg)
![Page 47: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/47.jpg)
![Page 48: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/48.jpg)
lipoatrophylipoatrophy
![Page 49: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/49.jpg)
![Page 50: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/50.jpg)
CataractCataract
![Page 51: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/51.jpg)
![Page 52: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/52.jpg)
![Page 53: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/53.jpg)
![Page 54: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/54.jpg)
![Page 55: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/55.jpg)
![Page 56: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/56.jpg)
![Page 57: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/57.jpg)
![Page 58: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/58.jpg)
![Page 59: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/59.jpg)
![Page 60: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/60.jpg)
![Page 61: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/61.jpg)
![Page 62: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/62.jpg)
DCCTDCCT
Microvascular Risk Reduction Microvascular Risk Reduction With Intensive TreatmentWith Intensive Treatment
Data from the Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
Reduction inComplication Relative Risk
Retinopathy 63%
Nephropathy 54%
Neuropathy 60%
![Page 63: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/63.jpg)
DCCT: Reduction of Risk for Appearance or Progression of Diabetic DCCT: Reduction of Risk for Appearance or Progression of Diabetic Complications With Intensive Glycemic ControlComplications With Intensive Glycemic Control
Complications Risk Reduction
(%)
95%
confidence interval
Appearance of retinopathy
(primary prevention) 76 62-85
Progression of retinopathy
(secondary prevention) 54 39-66
Urinary albumin excretion
(mg/24 h)
40
300
39
54
21-52
19-74
Clinical neuropathy at 5 yr* 60 38-74
* Excluding patients with clinical neuropathy at base line.N = 1441 patientsHoowerf BJ et al. Cleve Clin J Med. 1994;61:34-37.
![Page 64: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/64.jpg)
The EndThe End
![Page 65: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/65.jpg)
The following was written by Areteus the Cappadocian, sometime in the The following was written by Areteus the Cappadocian, sometime in the second to third century AD. This is from Dorothy Clark's "Source Book of second to third century AD. This is from Dorothy Clark's "Source Book of Medical History," originally published in 1942, and republished in 1960 by Medical History," originally published in 1942, and republished in 1960 by Dover. She cites as her source a translation of a Greek version done by Dover. She cites as her source a translation of a Greek version done by
Francis Adams in 1856 for the Sydenham Society.Francis Adams in 1856 for the Sydenham Society.
Diabetes is a wonderful affection, not very frequent among men, being a melting down of the flesh and limbs into urine. Its cause is of a cold and humid nature as in dropsy. The course is a common one, namely the kidneys and bladder; for the patients never stop making water, but the flow is incessant, as if from the opening of aqueducts. The nature of the disease then is chronic, and it takes a long period to form, but the patient is short-lived if the constitution of the disease be completely established; for the melting is rapid, the death speedy. Moreover, life is disgusting and painful; thirst unquenchable; excessive drinking, which however is disproportionate to the large quantity of urine for more urine is passed; and one cannot stop them either from drinking or making water. Or if for a time they abstain from drinking, their mouth becomes parched and their body dry; the viscera seem as if scorched up; they are affected with nausea, restlessness, and a burning thirst; and at no distant term they expire. Thirst as if scorched by fire.
![Page 66: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/66.jpg)
But by what method could they be restrained from making water? Or how can shame become more potent than pain? And even if they were to restrain themselves for a short time they become swelled in the loins, scrotum and hips; and when they give vent they discharge the collected urine, and the swellings subside for the overflow passes to the bladder. If the disease be fully established, it is strongly marked; but if it be merely coming on, the patients have the mouth parched, saliva white, frothy, as if from thirst (for the thirst is not yet confirmed), weight in the hypochondriac region. A sensation of heat or cold from the stomach to the bladder is, as it were, the advent of the approaching disease; they now make a little more water than usual and there is thirst but not yet great.
![Page 67: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/67.jpg)
But, if it increase still more, the heat is small indeed, but pungent, and seated in the intestines; the abdomen shrivelled, veins protuberant, general emaciation when the quantity of urine and thirst have already increased; and when, at the same time, the sensation appears in the extremity of the member, the patients immediately make water. Hence the disease appears to me to have got the name diabetes, as if from the Greek word which signifies a siphon, because the fluid does not remain in the body, but uses the man¼s body as a bladder whereby to leave it. They stand out for a certain time, though not for very long for they pass urine with pain, and the emaciation is dreadful; nor does any great portion of the drink get into the system, and many parts of the flesh pass out along with the urine.
![Page 68: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/68.jpg)
The cause of it may be that some of the acute diseases may have terminated in this; and during the crisis of the disease may have left some malignity lurking in the part. It is not improbable also, that something pernicious, derived from other diseases which attack the bladder and kidneys, may sometimes prove the cause of this affection. But if anyone is bit by the dipsas [a species of viper] the affection induced by the wound is of this nature; for the reptile, the dipsas, if it bite one, kindles up an unquenchable thirst. For they drink copiously, not as a remedy for thirst, but so as to produce repletion of the bowels, by the insatiable desire of drink. But if one be pained by the distention of the bowels and feel uncomfortable, and abstain from drink for a little, he again drinks copiously from thirst, and thus the evils alternate; for the thirst and the drink conspire together. Others do no pass urine, nor is their any relief from what is drank. Wherefore, what from insatiable thirst, an overflow of liquids, and distention of the belly, the patients have suddenly burst.
![Page 69: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/69.jpg)
TREATMENT The affection of diabetes is a species of dropsy, both in cause and
condition, differing only in the place by which the humour runs. For, indeed, in ascites the receptacle is the peritoneum, and it has no outlet, but remains there and accumulates. But in diabetes, the flow of the humour from the affected part and the melting are the same, but the defluction is determined to the kidneys and the bladder; and in dropsical cases this is the outlet when the disease takes a favorable turn; and it is good when it proves a solution to the cause, and not merely a lightening of the burden. In the latter disease the thirst is greater; for the fluid running off dries the body.
![Page 70: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/70.jpg)
But the remedies for the stoppage of the melting are the same as those for dropsy. For the thirst there is need for a powerful remedy for in kind it is the greatest of all sufferings; and when a fluid is drunk it stimulates the discharge of urine; and sometimes as it flows off it melts and carries away with it particles of the body. Medicines then which cure thirst are required, for the thirst is great with an insatiable desire of drink, so that no amount of fluid would be sufficient to cure the thirst. We must, then, by all means strengthen the stomach, which is the fountain of the thirst. When, therefore, you have purged with the hiera, use as Epithemes the nard, mastich, dates, and raw quinces; the juice of these with nard and rose oil is very good for lotions; their pulp with mastich and dates, form a cataplasm....
But the water used as drink is to be boiled with autumn fruit. The food is to be milk, and with it cereals, starch, groats of spelt, gruels. Astringent wines to give tone to the stomach, and these but little diluted, in order to dissipate and clear away the other humours; for thirst is engendered by saltish things.
![Page 71: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/71.jpg)
But the water used as drink is to be boiled with autumn fruit. The food is to be milk, and with it cereals, starch, groats of spelt, gruels. Astringent wines to give tone to the stomach, and these but little diluted, in order to dissipate and clear away the other humours; for thirst is engendered by saltish things.
![Page 72: Diabetes Type 2: Tight Control Sufyan Said, M.D. Staff Physician, CAVHS Assistant Professor, UAMS.](https://reader030.fdocuments.in/reader030/viewer/2022032723/56649d205503460f949f50ab/html5/thumbnails/72.jpg)
The following are excerpts from a letter written in 1894 to the Mayor of New The following are excerpts from a letter written in 1894 to the Mayor of New York City by Cyrus Edson, the Commissioner of Health. It was published in a York City by Cyrus Edson, the Commissioner of Health. It was published in a popular journal called Overland Monthly and Out West Magazine. Most of the popular journal called Overland Monthly and Out West Magazine. Most of the
letter discusses the "wholesomeness" of glucose (grape sugar) compared letter discusses the "wholesomeness" of glucose (grape sugar) compared with sugar derived from cane sugar, apparently a major issue in the late 19th with sugar derived from cane sugar, apparently a major issue in the late 19th
century. I have included only that part that describes diabetes and its two century. I have included only that part that describes diabetes and its two types as then recognized. types as then recognized.
...In addition to certain nervous varieties, due solely to disturbed nerve functions, diabetes is divided into two classes, of which one is due to excessive sugar formation in the blood and the other to diseased digestion, which prevents sugar from entering the circulation in the condition to be utilized by the system. The first of these classes is caused by disease of the liver; the second by disease of the pancreas. The latter form is by far the most dangerous and rapidly fatal. The former variety, on the other hand, may last many years.